Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
British Journal of Cancer|December 9, 2016
Perivascular PDGFR-β is an independent marker for prognosis in renal cell carcinomaMagnus Frödin, Artur Mezheyeuski, Sara Corvigno, et al.
Acta Oncologica (Stockholm, Sweden)|September 17, 2005
Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acidAnders Ullén, Lena Lennartsson, Ulrika Harmenberg, et al.
European Urology Open Science|May 9, 2022
Clinical T1a Renal Cell Carcinoma, Not Always a Harmless Disease-A National Register StudyTarik Almdalal, Pernilla Sundqvist, Ulrika Harmenberg, et al.
The Journal of Pathology|December 28, 2019
Perivascular Neuropilin-1 expression is an independent marker of improved survival in renal cell carcinomaEric Morin, Cecilia Lindskog, Martin Johansson, et al.
BMC Cancer|June 8, 2014
Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinomaJacob Farnebo, Per Grybäck, Ulrika Harmenberg, et al.
Acta Oncologica (Stockholm, Sweden)|August 25, 2005
Prostate cancer cell lines lack amplification: overexpression of HER2Anders Ullén, Lena Lennartsson, Ulrika Harmenberg, et al.
British Journal of Cancer|October 9, 2018
A minority-group of renal cell cancer patients with high infiltration of CD20+B-cells is associated with poor prognosisElin Sjöberg, Magnus Frödin, John Lövrot, et al.
Experimental and Molecular Pathology|August 9, 2021
Nuclear and stromal expression of Manic fringe in renal cell carcinomaWei Kang Cheng, Gurjeet Kaur, Elin Sjöberg, et al.
Cancer Management and Research|February 26, 2019
Real-world cost-effectiveness of targeted therapy in metastatic renal cell carcinoma in Sweden: a population-based retrospective analysisJosefine Redig, Johan Dalén, Ulrika Harmenberg, et al.
BJU International|January 27, 2011
Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinomaAgnes Benedict, Robert A Figlin, Per Sandström, et al.
Pageof 4